In February 2026, the Royal Decree was issued, regulating the selective financing procedure for certain health products – specifically, some types of medical aids – covered under the pharmaceutical benefit of the National Health System for non-hospitalized patients, and establishing the margins for their distribution and dispensing. The new regulation will update the old framework in place since 1996, establishing a clear, transparent, and structured system for selective financing and price-setting, with uniform criteria for the inclusion, modification, and exclusion of health products. The regulation will enter into force on July 1, 2026.